Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00029051
DRKS00029051
Recruiting
Not Applicable

Prospective observational study molecular tumor board of the Comprehensive Cancer Center Mainfranken of the University Hospital of Würzburg - MTB-WÜ

niversitätsklinikum Würzburg0 sites998 target enrollmentMay 20, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsC00-C97Malignant neoplasms

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C00-C97
Sponsor
niversitätsklinikum Würzburg
Enrollment
998
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 20, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum Würzburg

Eligibility Criteria

Inclusion Criteria

  • •Recommendation in the organ tumor board for a discussion in the molecular tumor board
  • •\- Guideline\-based and evidence\-based therapy already exhausted or to be exhausted in the foreseeable future
  • •\- Molecular genetic findings with unclear relevance
  • •\- Results of routine diagnostics not sufficiently informative

Exclusion Criteria

  • •\- Lack of ability to give consent or informed consent for registry study.
  • •\- Lack of consent for tissue and data release and lack of consent for genetic testing/panel diagnostics.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Prospective observational study of cancer-associated thrombosis in patients with newly diagnosed pancreatic cancerpancreatic cancer
JPRN-UMIN000044564Japanese Red Cross Okayama Hospital54
Recruiting
Not Applicable
Prospective observational study of cancer-associated thrombosis in patients with newly diagnosed biliary tract cancerbiliary tract cancer
JPRN-UMIN000048891Japanese Red Cross Okayama Hospital30
Active, not recruiting
Not Applicable
A clinical registry for longitudinal data on the clinical, psychosocial, and economic impact of lung cancer treatment in Italy
ISRCTN67197140niversity of L'Aquila1,000
Active, not recruiting
Not Applicable
Pathological response of chemotherapy in oral cancersHealth Condition 1: null- Statge IV Oral Cavity Cancers(BorderlineResectable)
CTRI/2016/02/006609A60
Recruiting
Not Applicable
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).N/A
DRKS00025847niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation1,000